Europska Unija - hrvatski - EMA (European Medicines Agency)

krka, d.d., novo mesto - Ирбесартан, hidroklorotiazid - hipertenzija - sredstva koja djeluju na sustav renin-angiotenzina - liječenje esencijalne hipertenzije. ova kombinacija fiksne doze je indicirana kod odraslih pacijenata čiji krvni tlak nije adekvatno kontroliran samo na irbesartan ili hidroklorotiazid sam.

Europska Unija - hrvatski - EMA (European Medicines Agency)

krka, d.d., novo mesto - irbesartan hidroklorid - hipertenzija - sredstva koja djeluju na sustav renin-angiotenzina - liječenje esencijalne hipertenzije. liječenje zatajenja bubrega u bolesnika s hipertenzijom i dijabetesom tipa 2 u okviru гипотензивные ljekovite hrane .

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

dr. theiss naturwaren gmbh, michelinstrasse 10, homburg, njemačka - tinktura brđankinog cvijeta (1:10), ekstrakcijsko otapalo: etanol 70% (v/v) - gel - 24 g/100 g - urbroj: 100 g gela sadrži 24 g tinkture iz arnica montana l., flos (brđankin cvijet) (1:10). ekstrakcijsko otapalo: etanol 70 % v/v

Europska Unija - hrvatski - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistična fibroza - drugi proizvodi respiratornog sustava - tablete orkambi rezultati za liječenje муковисцидоза (mv) kod bolesnika u dobi od 6 i više godina, koji su гомозиготами na mutacije f508del u genu cftr . orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Europska Unija - hrvatski - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemija, mieloid - antineoplastična sredstva - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - Толваптан - policistični bubreg, autosomno dominantan - diuretici, - jinarc je naznačeno da se usporiti napredovanje cista razvoj i bubrežnom insuficijencijom autosomno dominantnom policističnom bolešću bubrega (adpkd) u odraslih osoba s ckd pozornica 1 do 3 na početak liječenja s dokazima o brzo napreduje bolest.

Europska Unija - hrvatski - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - Толваптан - neprimjereni adh sindrom - diuretici, - liječenje odraslih bolesnika s hiponatrijemom sekundarnim sindromom neodgovarajućeg izlučivanja antidiuretičko-hormonskog hormona (siadh).

Europska Unija - hrvatski - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresivi - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Europska Unija - hrvatski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - homeostaza kalcija - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.